+1.650.627.4531 inquiry@medeortx.com
Contact Us| Find us on:

About Medeor Therapeutics

MAKING THE DREAM OF TRANSPLANT IMMUNE TOLERANCE A REALITY

MEDEOR THERAPEUTICS is a clinical-stage biotechnology company dedicated to discovery, development and commercialization of personalized cellular immunotherapies. We focus on improving outcomes in organ-transplant recipients and patients who suffer from hematologic conditions. Each of Medeor’s product candidates is made up of a unique composition of different types of hematopoietic donor-derived cells and is based on breakthrough technologies discovered at Stanford University and exclusively licensed by Medeor. These product candidates are designed to produce mixed chimerism, or the co-existence of blood and immune cells from both the donor and the recipient. For organ transplant patients, mixed chimerism can induce donor-specific immune tolerance, which reduces the likelihood of transplant organ loss, reduces or eliminates chronic immunosuppressive drug therapy, and improves patient outcomes. For hematologic conditions, mixed chimerism has the potential to reduce or eliminate disease symptoms.

Meet Our Team